Answers are grounded in this paper and cite their sources.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a systemic metabolic disorder that modifies the liver's response to acute injury. The presence of persistent metabolic stress, immune-inflammatory activation, organelle dysfunction, and impaired regenerative capacity collectively lower the threshold for acute hepatocellular injury (ALI) and hinder recovery. Consequently, individuals with MASLD exhibit heightened susceptibility to drug-induced liver injury (DILI), ischemia-reperfusion injury (IRI), and environmental toxins, resulting in more severe injury and a less favorable prognosis. This review examines ALI in MASLD, explores the mechanisms underlying increased susceptibility, and discusses how external factors exacerbate liver injury. It also summarizes key pathogenic mechanisms, proposes clinical management strategies, and identifies future research directions.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: